Advanced Gastric Adenocarcinoma Clinical Trial
Official title:
SAMSUNG MEDICAL CENTER
Verified date | December 2019 |
Source | Samsung Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Phase II, single-arm study of AZD6094 (Volitinib) in combination with docetaxel, in advanced
gastric adenocarcinoma patients with MET overexpression as a second-line treatment.
Volitinib is an orally available, potent, selective, small molecule c-MET inhibitor.
Subjects will receive Volitinib once daily (at the MTD determined from Phase Ib) for 21 days
as one cycle.
Docetaxel 60 mg/m2 will be administered via intravenous access once every 3 weeks.
To investigate the efficacy of volitinib when given in combination with docetaxel in patients
with advanced gastric adenocarcinoma harboring MET overexpression.
Status | Completed |
Enrollment | 2 |
Est. completion date | February 18, 2019 |
Est. primary completion date | February 18, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 20 Years |
Eligibility |
Inclusion Criteria: 1. Provision of fully informed consent prior to any study specific procedures. 2. Patients must be =20 years of age. 3. Advanced gastric adenocarcinoma (including GEJ) that has progressed during or after first-line therapy. - The 1st line regimen must have contained doublet 5-fluoropyrimidine and platinum based regimen. - Relapse within 6 months of completion of adjuvant/neoadjuvant chemotherapy containing doublet 5-fluoropyrimidine and platinum-based regimen could be considered as 1st line therapy. 4. Previous adjuvant/neoadjuvant chemotherapy is allowed, if completed more than 6 months prior to starting the 1st line therapy. 5. Provision or availability of biopsy sample for analysis; e.g mandatory pre-treatment biopsy, or available diagnostic biopsy of sufficient quantity/quality 6. Patients with MET overexpression 7. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations. 8. ECOG performance status 0-1. 9. Patients must have a life expectancy = 3 months from proposed first dose date. 10. Patients must have acceptable bone marrow, liver and renal function measured within 28 days prior to administration of study treatment as defined below: - Haemoglobin =9.0 g/dL (transfusion allowed) - Absolute neutrophil count (ANC) = 1.5 x 109/L - White blood cells (WBC) > 3 x 109/L - Platelet count =100 x 109/L (transfusion allowed) - Total bilirubin = 1.5 x institutional upper limit of normal (ULN) (does not include patients with Glibert's disease) - AST (SGOT)/ALT (SGPT) = 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be = 5x ULN - Serum creatinine =1.5 x institutional ULN 11. At least one measurable lesion that can be accurately assessed by imaging or physical examination at baseline and following up visits. 12. Negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day 1. for women of childbearing potential. 13. Provision of consent for mandatory biopsy at progression Exclusion Criteria: 1. More than one prior chemotherapy regimen (except for adjuvant/neoadjuvant chemotherapy with more than 6 month wash out period) for the treatment of gastric cancer in the advanced setting. 2. Any previous treatment with MET inhibitors 3. Any previous treatment with docetaxel. 4. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for =5 years. 5. HER2 positive patients (defined by HER2 3+ by immunohistochemistry or HER2 SISH +) 6. Patients unable to swallow orally administered medication. 7. Treatment with any investigational product during the last 28 days before the enrollment (or a longer period depending on the defined characteristics of the agents used). 8. Patients receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 3 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used). The patient can receive a stable dose of bisphosphonates or denosumab for bone metastases, before and during the study as long as these were started at least 4 weeks prior to treatment. 9. With the exception of alopecia, any ongoing toxicities (>CTCAE grade 1) caused by previous cancer therapy. 10. Intestinal obstruction or CTCAE grade 3 or grade 4 upper GI bleeding within 4 weeks before the enrollment. 11. Resting ECG with measurable QTcB > 480 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome. 12. Patients with cardiac problem as follows: uncontrolled hypertension (BP =150/95 mmHg despite medical therapy) Baseline Left ventricular ejection fraction below the LLN of <55% measured by echocardiography or institution's LLN for MUGA, Atrial fibrillation with a ventricular rate >100 bpm on ECG at rest , Symptomatic heart failure (NYHA grade II-IV), Prior or current cardiomyopathy, Severe valvular heart disease, Uncontrolled angina (Canadian Cardiovascular Society grade II-IV despite medical therapy), Acute coronary syndrome within 6 months prior to starting treatment 13. Female patients who are breast-feeding or child-bearing and Male or female patients of reproductive potential who are not employing an effective method of contraception 14. Any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV) 15. Patients currently receiving (or unable to stop use at least 2 weeks) prior to receiving the first dose of AZD6094, medications known to be potent inhibitors of CYP1A2 or CYP3A4, potent inducers of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung Medical Center | Seoul | Seoul, Korea, Republic Of |
Lead Sponsor | Collaborator |
---|---|
Samsung Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective response rate (ORR) by RECIST 1.1 | expected average of 24 weeks | ||
Secondary | Duration of response | expected average of 24 weeks | ||
Secondary | Disease control rate | 8 weeks | ||
Secondary | Overall survival (OS) | expected average of 24 weeks | ||
Secondary | progression-free survival (PFS) | expected average of 24 weeks | ||
Secondary | Number of subjects with Adverse Events as a Measure of safety and Tolerability | expected average of 24 weeks | ||
Secondary | Biomarker analysis | To see correlation between MetEx14, MET overexpression and to treatment response | 3years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04977193 -
A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma
|
Early Phase 1 | |
Recruiting |
NCT04993378 -
Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy
|
||
Recruiting |
NCT05583383 -
A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab
|
N/A | |
Completed |
NCT06238752 -
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC
|
Phase 2 | |
Recruiting |
NCT04209686 -
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT02240524 -
Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer
|
Phase 3 | |
Recruiting |
NCT06203600 -
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05677490 -
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
|
Phase 3 | |
Completed |
NCT02448329 -
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy
|
Phase 2 | |
Completed |
NCT02615730 -
PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05041153 -
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
|
Early Phase 1 | |
Terminated |
NCT02449655 -
Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy
|
Phase 2 | |
Completed |
NCT02449551 -
Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment
|
Phase 2 | |
Not yet recruiting |
NCT04174339 -
PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer
|
N/A | |
Completed |
NCT02599324 -
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06028737 -
Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT04675866 -
Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer
|
N/A | |
Completed |
NCT02447406 -
Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment
|
Phase 1/Phase 2 | |
Recruiting |
NCT03159819 -
Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma
|
N/A |